Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib
Indian Journal of Gastroenterology · 2025
DOI: 10.1007/s12664-025-01779-3 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Indian Journal of Gastroenterology, 2025. Verfasst von Arshdeep Singh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, 141 001, India. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Pyrimidines, Piperidines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The therapeutic target for ulcerative colitis (UC) has shifted towards deeper disease control. The real-world data on efficacy of tofacitinib in inducing histologic remission (HR) remains limited. We evaluated the real-world efficacy of tofacitinib in achieving endoscopic remission (ER) and HR. METHODS: A prospective observational cohort study was conducted from January 2022 to June 2024. Adult patients with moderate-to-severe UC (Mayo score ≥ 6, endoscopic subscore ≥ 2) who responded to tofacitinib induction by week 16 were included. Paired endoscopic and histologic assessments were performed at baseline and week 48. Endoscopic disease activity was graded using the Mayo endoscopic score (MES), while histologic activity was evaluated using the Nancy index (NI). The primary outcome was combined endoscopic-histologic remission (EHR), defined as MES of 0 and a NI of 0, at week 48. The key secondary outcomes included ER, HR, histologic endoscopic mucosal improvement (HEMI) and endoscopic improvement histologic remission (EIHR). RESULTS: Total 86 patients who received tofacitinib induction therapy were evaluated. Nine non-responders at 16 weeks were excluded and 77 patients (median age 37 years, 38 [49%] females) were analyzed. At week eight, clinical response and remission were achieved in 66 (85.7%) and 37 (48.1%) patients, respectively. At week 48, 57 (74.02%) patients maintained clinical response. Median MES and NI were 1 (IQR 0-3) and 3 (IQR 0-3), respectively. Combined EHR was achieved in 22 (28.6%) patients, while ER and HR were observed in 30 (38.9%) and 29 (37.6%) patients, respectively. HEMI was noted in 32 (41.6%) patients, while EIHR was seen in 27 (35.1%) patients. No significant predictors of ER, HR or combined EHR were identified. No serious adverse effects were reported. CONCLUSIONS: Tofacitinib is effective in achieving combined EHR, ER and HR. These findings support the potential for histologic healing as a therapeutic target for UC in real world.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, 141 001, India.
- Research and Development Centre, Dayanand Medical College and Hospital, Ludhiana, 141 001, India.
- Digestive Diseases Care Foundation, Ludhiana, 141 001, India.
- Department of Pharmacology, Dayanand Medical College and Hospital, Ludhiana, 141 001, India.
- Department of Pathology, Dayanand Medical College and Hospital, Ludhiana, 141 001, India.
- Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, 141 001, India. vandana_midha2@yahoo.co.in.
Zitieren
APA
Singh, A., Bhardwaj, A., Jain, D., Sharma, R., Singh, D., Mahajan, R., Kaur, K., Singh, A., Narang, V., Kaur, H., Singh, M., Gupta, P., Sehgal, T., Midha, V., & Sood, A. (2025). Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib. Indian Journal of Gastroenterology. https://doi.org/10.1007/s12664-025-01779-3
Vancouver
Singh A, Bhardwaj A, Jain D, Sharma R, Singh D, Mahajan R, et al. Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib. Indian Journal of Gastroenterology. 2025. doi:10.1007/s12664-025-01779-3
BibTeX
@article{Singh2025,
author = {Singh, Arshdeep and Bhardwaj, Arshia and Jain, Devanshi and Sharma, Riya and Singh, Dharmatma and Mahajan, Ramit and Kaur, Kirandeep and Singh, Aminder and Narang, Vikram and Kaur, Harpreet and Singh, Manavjot and Gupta, Pritish and Sehgal, Tanisha and Midha, Vandana and Sood, Ajit},
title = {Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib},
journal = {Indian Journal of Gastroenterology},
year = {2025},
doi = {10.1007/s12664-025-01779-3}
}
EUVIMED